Drupal.behaviors.print = function(context) {window.print();window.close();}>
Dx Focus: Quidel AmpliVue C. Difficile; Spartan Bioscience CYP2C19 Test Starts Clinical Trial
December 20, 2012
Dx Focus: Quidel AmpliVue C. Difficile; Spartan Bioscience CYP2C19 Test Starts Clinical Trial
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Quidel Obtains CE Mark for AmpliVue C. Difficile, Company's First Handheld MDx Test
March 29, 2012 / PCR Insider
With BioHelix Acquisition, Quidel Brings Isothermal Amplification Tech in House
May 9, 2013 / PCR Insider
Quidel Continues to Advance Trio of MDx Initiatives; On Target to Complete All by End of '13
March 1, 2012 / PCR Insider
FDA OK of Life Tech, Quidel C. Diff Assay Sets Stage for Future Cleared Tests on QuantStudio Dx
March 21, 2013 / PCR Insider
FDA Clears Quidel C. difficile Assay for Life Tech's QuantStudio Dx and 7500 Fast Dx PCR Instruments
March 18, 2013 / GenomeWeb Daily News